Voya Investment Management LLC Reduces Stock Position in Penumbra, Inc. $PEN

Voya Investment Management LLC trimmed its position in shares of Penumbra, Inc. (NYSE:PEN) by 8.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 148,271 shares of the company’s stock after selling 13,531 shares during the quarter. Voya Investment Management LLC’s holdings in Penumbra were worth $37,560,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in PEN. Newbridge Financial Services Group Inc. bought a new position in shares of Penumbra in the second quarter worth about $30,000. Parkside Financial Bank & Trust raised its position in Penumbra by 70.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock worth $41,000 after purchasing an additional 66 shares during the period. State of Wyoming purchased a new stake in shares of Penumbra during the second quarter valued at $64,000. AlphaQuest LLC purchased a new stake in Penumbra in the 1st quarter valued at about $66,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Penumbra by 209.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock worth $70,000 after buying an additional 184 shares during the period. 88.88% of the stock is currently owned by institutional investors.

More Penumbra News

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: JPMorgan upgraded PEN from Neutral to Overweight and bumped its target to $370 (from $275), signaling stronger conviction in Penumbra’s growth trajectory and implying meaningful upside vs. the current share level. JP Morgan Upgrades Penumbra (PEN)
• Positive Sentiment: Truist raised its price target to $370 from $312 and reiterated a Buy, reinforcing the bullish view and matching JPMorgan’s $370 target that implies roughly mid‑teens upside from current levels. Penumbra upgraded to overweight from neutral at JPMorgan
• Positive Sentiment: Additional price-target lifts from RBC (to $355 from $325) and Canaccord (to $359 from $355) add to the consensus upward drift in sell‑side expectations. These moves tighten the buy-side narrative around recurring CAVT adoption and international growth. Penumbra price target raised to $359 from $355 at Canaccord Penumbra price target raised to $355 from $325 at RBC Capital
• Positive Sentiment: Needham reiterated a Buy rating, supporting the positive analyst tone and reducing near‑term downside risk from the sell‑side. Needham maintains Penumbra (PEN) buy recommendation
• Positive Sentiment: Clinical/outcomes coverage: a published evaluation of Penumbra’s CAVT in intermediate‑risk pulmonary embolism (PE) patients highlights outcomes and resource‑utilization benefits—supportive evidence for broader clinical adoption and reimbursement discussions. Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients
• Neutral Sentiment: Media/awareness: Bloomberg’s healthcare segment highlighted Penumbra’s efforts to expand CAVT awareness—positive for long‑term market penetration but more of a brand/voice play than an immediate revenue driver. Vanguards of Health Care: Penumbra Expands CAVT Awareness

Wall Street Analysts Forecast Growth

PEN has been the subject of a number of recent analyst reports. Evercore ISI reiterated an “outperform” rating and issued a $286.00 target price on shares of Penumbra in a research note on Thursday, November 6th. Royal Bank Of Canada restated an “outperform” rating and set a $355.00 target price on shares of Penumbra in a research report on Wednesday. Robert W. Baird set a $345.00 price target on Penumbra in a report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a research report on Monday, December 15th. Finally, Canaccord Genuity Group raised their price objective on Penumbra from $355.00 to $359.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $333.47.

Penumbra Trading Up 0.2%

PEN stock opened at $315.98 on Friday. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $320.00. The business’s 50-day moving average is $274.47 and its 200 day moving average is $260.87. The company has a current ratio of 6.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock has a market cap of $12.37 billion, a price-to-earnings ratio of 75.59, a PEG ratio of 2.61 and a beta of 0.66.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.07. The business had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The business’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.85 earnings per share. On average, sell-side analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity

In other Penumbra news, Director Harpreet Grewal sold 100 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $292.98, for a total value of $29,298.00. Following the completion of the transaction, the director owned 8,416 shares of the company’s stock, valued at $2,465,719.68. This trade represents a 1.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Johanna Roberts sold 300 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $300.13, for a total transaction of $90,039.00. Following the transaction, the executive vice president owned 63,836 shares of the company’s stock, valued at approximately $19,159,098.68. The trade was a 0.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 34,744 shares of company stock worth $10,387,474 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.